EFC16033 & EFC16033 Actigraphy (Gemini)

EFC16033 & EFC16033 Actigraphy (Gemini) A biological drug to treat relapsing Multiple Sclerosis (RMS)

$

This study evaluates the safety and effectiveness of SAR442168 compared to teriflunominde (Aubagio).

$

This trial is not accepting new patients.

$

The purpose of this study is to assess the efficacy and safety of the study drug SAR442168 compared with teriflunomide (Aubagio) in participants with relapsing Multiple Sclerosis (RMS)

$

Basic Enrollment Criteria:

  • Age 18-55 years old, Male & Female
  • Willing to comply with study visits and requirements
$

Study Length:

  • approximately 3 years

Participate In This Study